Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 22, 2005. The report details a share repurchase transaction executed under authority granted at the Annual General Meeting on May 25, 2005, and discloses changes in directors' interests regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 500,000 Ordinary shares.
- Purchase Date: June 21, 2005.
- Price per Share: 1,357.7 pence.
- Treasury Holdings Post-Purchase: 99,903,000 shares.
- Shares in Issue (excluding Treasury): 5,843,164,079 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 500,000 shares, which are now held in Treasury. Additionally, the GlaxoSmithKline Employee Trust transferred 2,338 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on June 21, 2005.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase (500,000 shares x 1,357.7 pence).
- Confirm the updated total share capital structure, noting the 99,903,000 shares held in Treasury.
- Review the impact of the 2,338 shares transferred from the GSK Trust to employee option plan participants on director interest disclosures.
- Note that this filing does not contain quarterly or annual financial performance data.